P38 Molecular Targeting for Next-Generation Multiple Myeloma Therapy.

ABSTRACT: Resistance to therapy and disease progression are the main causes of mortality in most cancers. In particular, the development of resistance is an important limitation affecting the efficacy of therapeutic alternatives for cancer, including chemotherapy, radiotherapy, and immunotherapy. Signaling pathways are largely responsible for the mechanisms of resistance to cancer treatment and progression, and multiple myeloma is no exception. p38 mitogen-activated protein kinase (p38) is downstream of several signaling pathways specific to treatment resistance and progression. Therefore, in recent years, developing therapeutic alternatives directed at p38 has been of great interest, in order to reverse chemotherapy resistance and prevent progression. In this review, we discuss recent findings on t

SUBMITTER: Morales-Martinez M 

PROVIDER: S-EPMC10813990 | biostudies-literature | 2024 Jan

REPOSITORIES: biostudies-literature